Related Experiment Video
Updated: Apr 11, 2026
10:08
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
Published on: February 17, 2018
14.1K
Chronic heart failure: what does the horizon look like?
1Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas, USA.
Current Opinion in Cardiology
|June 8, 2015
Summary
Novel therapies like LCZ696 and ivabradine show promise for heart failure with reduced ejection fraction (HFrEF). However, effective treatments for heart failure with preserved ejection fraction (HFpEF) remain elusive, despite ongoing research.
Area of Science:
- Cardiology
- Pharmacology
- Medical Devices
Background:
- Heart failure, encompassing both reduced (HFrEF) and preserved ejection fraction (HFpEF) types, presents a significant global health challenge.
- Recent advancements aim to improve outcomes and reduce hospitalizations for heart failure patients.
Purpose of the Study:
- To review the latest developments in HFrEF and HFpEF treatment strategies.
- To highlight novel therapeutic agents and monitoring devices impacting heart failure care.
Main Methods:
- Review of recent clinical trials and FDA-approved therapies for HFrEF and HFpEF.
- Analysis of efficacy and safety data for new heart failure interventions.
Main Results:
- LCZ696 (valsartan and neprilysin inhibitor) significantly reduced mortality and hospitalizations in HFrEF compared to enalapril.
- Ivabradine and coenzyme Q10 demonstrated efficacy as adjunctive therapies in HFrEF.
- Clinical trials for HFpEF have yielded disappointing results thus far.
- A novel pulmonary artery pressure monitoring device received FDA approval, potentially reducing readmissions.
Conclusions:
- Novel therapies such as LCZ696 and ivabradine offer new hope for managing HFrEF.
- Current evidence does not support novel interventions modifying the natural course of HFpEF.
- Pulmonary artery pressure monitoring may offer a future strategy for reducing HFpEF readmissions.
Related Concept Videos
01:17Pathophysiology of Heart Failure
4.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.7K
01:30Heart Failure IV: Classification and Diagnostic Evaluation
618
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
618
01:27Heart Failure I: Introduction
1.3K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.3K
01:29Heart Failure II: Pathophysiology
1.5K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.5K
01:30Heart Failure V: Medical Management
567
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
567
01:22Heart Failure VI: Adjunct Therapies
599
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
599